Clinical Trial: Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07423572) titled 'Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)' on Feb. 14.

Brief Summary: A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition: Refractory Idiopathic Membranous Nephropathy

Intervention: DRUG: CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

Patie...